Neurology

Review top news and interview highlights from the week ending December 5, 2025.

Colleen Caleshu, MS, CGC, the senior director of research and real world data at Genome Medical, discussed a session she chaired at the NSGC Annual Conference.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

In episode 7 of ImmunoLogic, Anusha Kalbasi, MD, discussed his research on the use of IL-9 to enhance CAR-T efficacy.

The research director at the Clinic for Special Children discussed how screening at-risk patients can speed up diagnosis and treatment of spinal muscular atrophy.

Catch up on any of the key FDA news stories you may have missed last month, with coverage highlights from the CGTLive® team.

Review top news and interview highlights from the week ending November 28, 2025.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The FDA also added a new Warnings & Precaution for heightened susceptibility to serious infections caused by immunosuppression.

According to Novartis, it is the first gene replacement therapy to have been approved “for this broad population.”

Review top news and interview highlights from the week ending November 21, 2025.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The senior director of research and real world data at Genome Medical discussed important considerations for genetic counselors thinking about using AI tools in their practice.

The senior director of research and real world data at Genome Medical discussed a session she chaired at the NSGC Annual Conference.

According to Intellia, the FDA placed clinical holds on both MAGNITUDE and MAGNITUDE-2 on October 29, 2025.

Review top news and interview highlights from the week ending November 7, 2025.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Naji Gehchan, MD, MBA, the chief medical and development officer of Kyverna Therapeutics, went over new data the company presented at AANEM’s 2025 meeting.

Deborah Phippard, PhD, and Renier Brentjens, MD, PhD, discussed how AI will affect cell and gene therapy research and practice.

uniQure pointed out that this new feedback stands in contrast to its previous communications with the FDA in several Type B meetings.

Catch up on any of the key data updates you may have missed last month, with coverage highlights from the CGTLive® team.

Catch up on any of the key FDA news stories you may have missed last month, with coverage highlights from the CGTLive® team.

Review top news and interview highlights from the week ending October 31, 2025.

Deborah Phippard, PhD, shared her thoughts with Renier Brentjens, MD, PhD, on reducing costs for cell and gene therapy products.